KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) announced that the company will be presenting at the Jefferies 2014 Global Healthcare Conference Tuesday, June 3, New York City, NY Corporate Presentation by KaloBios President & CEO David Pritchard, with Webcast 4:30 – 5:00 pm Eastern/ 1:30 – 2:00 pm Pacific. KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) weekly performance is 11.73%. On last trading day company shares ended up $2.00. Analysts mean target price for the company is $7.50. KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) distance from 50-day simple moving average (SMA50) is -15.35%.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a clinical-stage pharmaceutical company, will be added to the Morgan Stanley Capital International (MSCI) Global Micro Cap Index, effective May 30, 2014. Tonix develops first-in-class medicines for common disorders of the central nervous system, including fibromyalgia (FM), post-traumatic stress disorder (PTSD) and episodic tension-type headache. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares advanced 6.64% in last trading session and ended the day on $9.96. TNXP return on assets is -253.50%.Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) quarterly performance is -30.06%.
AbbVie Inc.’s (NYSE:ABBV) shares continue to inch up since the company announced its new drug submission (NDS) to Health Canada for its investigational hepatitis C virus (HCV) infection therapy. Shares were up 0.7% following the company’s announcement. Overall shares increased 1.3% since the announcement. AbbVie Inc. (NYSE:ABBV) shares moved up 0.15% in last trading session and was closed at $54.07, while trading in range of $53.82 – $54.61. AbbVie Inc. (NYSE:ABBV) year to date (YTD) performance is 4.12%.
Echo Therapeutics, Inc. (NASDAQ:ECTE) a medical device company developing its Symphony((R)) CGM System as a non-invasive, wireless continuous glucose monitoring system, announced that it has mailed a letter to stockholders. Echo’s letter questions the qualifications of the Platinum Group’s nominee for election to the Echo Board of Directors, Shepard M. Goldberg, and highlights the stark contrast between Mr. Goldberg’s experience and that of the Echo Board’s highly qualified and very experienced nominee, Robert F. Doman. Echo Therapeutics Inc. (NASDAQ:ECTE) ended the last trading day at $1.58. Company weekly volatility is calculated as 7.76% and price to cash ratio as 2.34.Echo Therapeutics Inc. (NASDAQ:ECTE) showed a negative weekly performance of -9.71%.
ITI (NASDAQ:ITCI) VP Lawrence P. Wennogle sold 6,000 shares of ITI stock on the open market in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $15.00, for a total transaction of $90,000.00. Following the completion of the transaction, the vice president now directly owns 106,500 shares of the company’s stock, valued at approximately $1,597,500. ITI Inc. (NASDAQ:ITCI) weekly performance is -1.00%. On last trading day company shares ended up $14.88. Analysts mean target price for the company is $29.67. ITI Inc. (NASDAQ:ITCI) distance from 50-day simple moving average (SMA50) is -11.93%.